GB-115 for Health & Longevity

Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Ranquilon, Rankvilon, GB115, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, Phenylhexanoyl-glycyl-L-tryptophan amide

Motivation

GB-115 is a small synthetic molecule built from two amino acids and sold in Russia as a prescription anti-anxiety drug under the brand name Ranquilon. It was designed to block the action of a gut and brain messenger that can provoke panic-like fear when given to people. Its appeal is the prospect of calming anxiety without the sedation, muscle weakness and dependence linked to classic tranquilizers.

The compound came out of a decades-long Russian program that turns the brain’s small protein messengers into oral drugs. Its human studies were run in Russia, largely by its developer and its manufacturer, in people with anxiety tied to stress-related exhaustion or to difficulty adjusting to life events. Elsewhere, it circulates online as an unregulated powder among self-experimenters. Western drug companies tested blockers of the same messenger for anxiety decades earlier, making this compound a test of an older, still unsettled idea.

This review examines the evidence for and against using GB-115 for health and longevity: how it acts in the brain, how strong the human data are, which risks and gaps exist, and what is known about dosing, sourcing and monitoring for adults who actively manage their stress resilience.

Benefits - Risks - Protocol - Conclusion

This section lists in-depth reviews of GB-115 and of the cholecystokinin system it targets.

Only four items qualified: all other in-depth GB-115 material is primary research from the same developer or manufacturer, a registry or database entry, or forum discussion. No content on GB-115 was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; the compound is a Russian prescription drug with almost no English-language coverage outside the scientific literature.

Grokipedia

  • GB-115

    An AI-written encyclopedia entry summarizing preclinical work, unblinded pilot data, the responder and adverse-event rates of the large confirmatory (Phase III) trial, and Russian approval in December 2023.

Examine

No Examine article on GB-115 exists. GB-115 is a prescription medication in Russia, and Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on GB-115 exists. GB-115 is a prescription medication in Russia, and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

No systematic reviews or meta-analyses for GB-115 were found on PubMed as of 11/08/2026.

Neither the claimed anti-anxiety effect nor the principal risks of GB-115, nor cholecystokinin receptor blockade for anxiety as a class, are covered by a systematic review or meta-analysis.

Mechanism of Action

  • Target system: Cholecystokinin (CCK) is a gut hormone and the most abundant brain neuropeptide (a small protein messenger between nerve cells). A narrative review notes that its fragment CCK-4, given into a vein, provokes panic attacks in a dose-related way (Rehfeld 2021).
  • Design: GB-115 is a dipeptide (two-amino-acid molecule) modeled on CCK-4; in work by its developers at the Zakusov Institute, which holds a direct interest, L-tryptophan versions reduced anxiety in animals, while mirror-image D-tryptophan versions increased it (Gudasheva 2007).
  • Competing receptor accounts: Early Zakusov work described GB-115 as a CCK2 receptor blocker (Kolik 2007). In mice, activating CCK2 receptors abolished its anti-anxiety effect (Kolik 2012). The Russian label instead calls it a low-affinity blocker of CCK1 receptors (Russian label Ranquilon (RLS copy)). Which receptor carries the clinical effect is unresolved.
  • Phenotype dependence: In rodents, GB-115 reduced anxiety in MR rats but not in MNRA rats, strains that differ in stress reactivity (Kolik 2003).
  • Pharmacology: Plasma half-life (time for blood levels to halve) is about 1.3–1.8 hours (Russian label Ranquilon (RLS copy)); apparent volume of distribution (how widely the drug spreads into tissues) is 2.5 L/kg (Russian label Ranquilon (RLS copy)); animal data show it reaches the brain (Russian label Ranquilon (RLS copy)); human liver enzyme preparations break it down slowly (Russian label Ranquilon (RLS copy)). The cytochrome P450 enzymes (main liver drug-metabolizing enzymes) involved are unidentified. In animals, absolute oral bioavailability (share reaching the blood) was 4.65% (Boyko 2007).

Historical Context & Evolution

GB-115 grew out of the dipeptide drug-design program at the V.V. Zakusov Institute of Pharmacology in Moscow, which also produced the nootropic (cognition-targeting drug) Noopept (Gudasheva 2018). Its original intended use was as a selective anxiolytic (anti-anxiety drug) free of the sedation, muscle relaxation and dependence seen with benzodiazepines (sedative anti-anxiety drugs such as diazepam).

The rationale came from 1980s–1990s findings that CCK-4 provokes panic in humans. Western companies then tested CCK2 receptor blockers in anxiety: in 88 people with generalized anxiety disorder (persistent, hard-to-control worry), CI-988 did not outperform placebo on the Hamilton Anxiety Rating Scale (HARS, a clinician-rated 0–56 anxiety score) (Adams 1995), and L-365,260 did not outperform placebo in panic disorder (recurrent unexpected panic attacks) (Kramer 1995). A panic disorder trial team suggested that poor pharmacokinetics (absorption and blood levels) of CI-988 might explain its null result (Pande 1999), so the theory was left untested rather than refuted.

Zakusov researchers pursued a peptide route instead, reporting oral anti-anxiety activity in rodents (Kolik 2013), a 31-patient pilot study in generalized anxiety disorder (Neznamov 2019), and, with the manufacturer Valenta Pharm, which holds a direct financial interest, a placebo-controlled Phase III (large confirmatory) trial (Karavayeva 2024). Russia registered Ranquilon as a prescription anxiolytic in December 2023 (registration LP-No(004206)-(RG-RU)), as listed in the Vidal drug reference (Vidal monograph Ranquilon). Interest in GB-115 for health optimization arises from this non-sedating profile and from online self-experimentation communities; no study has examined aging or lifespan.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: all controlled human data come from trials run or sponsored by a single development program (Zakusov Institute and Valenta Pharm), with no independent replication.

Medium 🟩 🟩

GB-115 reduces clinician-rated anxiety linked to neurasthenia (persistent stress-related exhaustion) or adjustment disorder (distress after a life change). Evidence: a 220-patient randomized (assigned by chance), double-blind (neither patients nor doctors knew assignments), placebo-controlled Phase III trial (Karavayeva 2024); a 168-patient dose-finding trial in which only 6 mg daily beat placebo on the main outcome (Goncharov 2023); and a 200-patient open-label (unblinded) Phase IV (post-approval) comparison with fabomotizole (a Russian non-sedating anxiolytic) (Karavayeva 2026). All were four-week trials sponsored by manufacturer Valenta Pharm that excluded generalized anxiety disorder.

Magnitude: In the Phase III trial, 70.0% on GB-115 versus 24.5% on placebo achieved at least a 50% fall in HARS score at day 29, a difference of 45.5 percentage points (Karavayeva 2024).

Reduced fatigue in anxious patients

Alongside anxiety, GB-115 lowered self-rated fatigue on the Multidimensional Fatigue Inventory (MFI-20, a 20-item fatigue questionnaire), consistent with the mild stimulating quality its developers describe. Evidence: secondary endpoints of the Phase III trial (Karavayeva 2024), a greater MFI-20 improvement than with fabomotizole in the open-label Phase IV trial (Karavayeva 2026), and a post-hoc analysis (one decided after data collection) of 25 pilot-study patients with generalized anxiety disorder (Dorofeeva 2022). All come from the same development program, and the controlled trial’s abstract gives no size for the difference over placebo.

Magnitude: Median MFI-20 score fell from 70 to 28 over 21 days of 6 mg daily (no control group) (Dorofeeva 2022); the Phase III abstract reports a significant advantage over placebo without a figure (Karavayeva 2024).

Low 🟩

Faster reaction time and attention

In 25 patients with generalized anxiety disorder taking 6 mg daily, reaction time and attention tests improved from day 7 (Dorofeeva 2022), in line with the 31-patient pilot (Neznamov 2019). Neither study had a control group, so practice effects (gains from repeating a test) cannot be excluded.

Magnitude: Mean reaction time fell from 449.19 ms at baseline to 406.5 ms at day 21 (no control group) (Dorofeeva 2022).

Improved sleep in anxious patients ⚠️ Conflicted

A pilot study of 31 patients with generalized anxiety disorder reported a beneficial effect of GB-115 on sleep disturbances (Neznamov 2019). It had no control group, and the label lists insomnia among adverse reactions (Russian label Ranquilon (RLS copy)). Net reading: a sleep benefit is unconfirmed, and insomnia is possible.

Magnitude: Not quantified in available studies. The only report is an uncontrolled pilot whose abstract gives no sleep score.

Speculative 🟨

Reduced alcohol intake

In rats with long-term alcohol access, GB-115 for 14 days reduced daily consumption only in high-emotionality animals (Kolik 2016). Animal data only.

Antidepressant-like effect

In mice, an anti-anxiety dose shortened immobility in a forced-swim despair test, less strongly than amitriptyline (an older antidepressant) (Kolik 2011). Animal data only.

Anti-inflammatory and immune effects

In mice, GB-115 reduced experimental inflammation and eased autoimmune brain inflammation (Shipaeva 2011), and stimulated macrophage (immune scavenger cell) activity (Shipaeva 2008). Mechanistic animal data only.

Lower stress-hormone ratio

In four isolated rhesus monkeys, GB-115 tablets reduced the cortisol to DHEA-S (dehydroepiandrosterone sulfate, an adrenal hormone) ratio, a stress marker (Panchenko 2025). Animal data, unvalidated biomarker.

Benefit-Modifying Factors

  • Genetic background: No human pharmacogenetic (gene-based drug response) data exist. GB-115 reduced anxiety in MR rats but not MNRA rats, strains bred for opposite stress reactivity (Kolik 2003), suggesting inherited stress style may decide who responds.
  • Baseline anxiety level: The Phase III trial enrolled only HARS scores of 18–24 with MFI-20 fatigue scores above 50 (NCT05586789). Benefit in mild, severe or undiagnosed anxiety is untested.
  • Sex: About two-thirds of participants were women in the dose-finding trial (Goncharov 2023) and the pilot (Neznamov 2019); no sex-specific results have been reported, so no sex difference in benefit is known.
  • Pre-existing conditions: The Phase III trial excluded generalized anxiety disorder, panic disorder, depression and substance dependence (NCT05586789). Benefit in these conditions rests only on an uncontrolled pilot or is unknown.
  • Age: The Phase III trial enrolled adults aged 18–70 (NCT05586789); the label states use in older adults has not been studied (Russian label Ranquilon (RLS copy)).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from four-week, sponsor-run trials of one development program, with no independent or long-term safety study.

Medium 🟥 🟥

Mild neurological, mood, sleep and digestive adverse events ⚠️ Conflicted

Label-listed reactions include headache, dizziness, sleepiness or insomnia, irritability, mood swings, daydreaming, attention problems, weakness, tremor, taste disturbance, nausea, diarrhea, joint pain, reversible blurred vision and proteinuria (protein in the urine) (Russian label Ranquilon (RLS copy)). Phase III events were all mild and numerically more common on GB-115 (Karavayeva 2024); the dose-finding trial found no excess over placebo, with few moderate and one severe event (Goncharov 2023). No serious event or treatment stop occurred. Net reading: mild events affect about one in four users; excess over placebo is unproven.

Magnitude: Adverse events occurred in 25.5% on GB-115 versus 14.6% on placebo in Phase III (not statistically significant) (Karavayeva 2024); at 6 mg daily in Phase II, 26.2% versus 35.7% on placebo (Goncharov 2023); and 16.0% versus 12.0% on fabomotizole in Phase IV (Karavayeva 2026).

Low 🟥

Increased hunger and calorie intake

CCK is a satiety (fullness) signal acting through CCK1 receptors. In healthy men, the CCK1 blocker loxiglumide increased hunger and calorie intake versus saline (Beglinger 2001). Indirect: different compound, intravenous route and higher receptor blockade than low-affinity oral GB-115; not reported in GB-115 trials.

Magnitude: Calorie intake rose 10% with loxiglumide versus saline (Beglinger 2001); no GB-115 figure exists.

Reduced gallbladder emptying

CCK triggers gallbladder contraction after meals. In healthy volunteers, intravenous loxiglumide dose-dependently blocked meal-induced emptying and enlarged the fasting gallbladder (Niederau 1989). Indirect: different compound and route; gallbladder function was not measured in GB-115 trials.

Magnitude: Loxiglumide markedly increased gallbladder volume when given alone; the abstract reports no outcome figure, and none exists for GB-115 (Niederau 1989).

Speculative 🟨

Anxiety from the wrong mirror-image form

The D-tryptophan analogues of GB-115 increased anxiety in animals (Gudasheva 2007). Unverified grey-market powder containing the wrong form could, in theory, worsen anxiety. Mechanistic basis only.

Strengthened opioid effects

In mice, GB-115 strengthened morphine pain relief through opioid (morphine-type pain-relief) mechanisms (Kolik 2007). Additive opioid effects in humans are untested. Animal data only.

Unknown long-term effects

Six-month dosing in rats and rabbits caused no irreversible organ changes (Sorokina 2010), but no human has been studied beyond four weeks. Animal data only.

Risk-Modifying Factors

  • Genetic factors: No pharmacogenetic data exist; the enzymes that metabolize GB-115 have not been identified, so variants in drug-metabolizing genes cannot be assessed.
  • Baseline biomarkers: The Phase III trial excluded people with liver enzymes or bilirubin above three times normal and an estimated glomerular filtration rate (eGFR, a kidney filtration measure) of 59 mL/min/1.73 m² or lower (NCT05586789). Risk at abnormal baseline values is therefore unknown.
  • Sex: No sex-specific safety analysis has been published; women of childbearing potential face a separate concern because the label contraindicates use in pregnancy (Russian label Ranquilon (RLS copy)).
  • Pre-existing conditions: Kidney and liver impairment have not been studied (Russian label Ranquilon (RLS copy)). Gallbladder disease may raise risk if CCK1 blockade slows emptying (inferred from loxiglumide data; no GB-115 data).
  • Age: Safety in adults over 70 is unstudied; older adults have higher rates of gallstones and falls, which could amplify dizziness or gallbladder effects (inferred; no GB-115 data).

Key Interactions & Contraindications

Documented interactions:

  • Food: Taking GB-115 after a meal raised total exposure about 1.26-fold versus fasting, with peak level within standard equivalence limits (80–125%) (Dorofeeva 2023). Consequence: about 26% higher exposure with food; the label directs dosing during or after meals (Russian label Ranquilon (RLS copy)).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Benzodiazepines and other sedative anxiolytics (diazepam, alprazolam, phenazepam): Inferred additive calming effects on the central nervous system; consequence: excess drowsiness and impaired driving. The Phase III trial prohibited anxiolytics and sedatives (NCT05586789). Mitigation: no driving until the combined effect is known.
  • Opioids (morphine, codeine, tramadol): Inferred from mouse data showing strengthened morphine pain relief; consequence: possibly stronger opioid effects, including sedation. Mitigation: lowest effective opioid dose and observation for drowsiness.
  • Antidepressants (sertraline, escitalopram, venlafaxine): Inferred additive effects on anxiety circuits; the Phase III trial excluded antidepressant users (NCT05586789), so combined effects are unknown. Consequence: unpredictable mood or sleep effects. Mitigation: introducing one agent at a time.
  • Sedating antihistamines (diphenhydramine, doxylamine) and alcohol: Inferred additive drowsiness with the sleepiness listed on the label (Russian label Ranquilon (RLS copy)); consequence: impaired alertness. Mitigation: no combination before driving.
  • Calming supplements (L-theanine, kava, ashwagandha, magnesium, valerian): Inferred additive anti-anxiety or sedative effects; consequence: excess drowsiness. Mitigation: starting one at a time.
  • Other CCK receptor blockers (proglumide, dexloxiglumide): Inferred additive CCK1 blockade; consequence: greater appetite and gallbladder effects. Avoid combining.

Populations who should avoid GB-115:

  • Hypersensitivity to the active substance or tablet ingredients: absolute contraindication (Russian label Ranquilon (RLS copy)).
  • Pregnancy and breastfeeding: contraindicated; stop if pregnancy occurs (Russian label Ranquilon (RLS copy)).
  • People under 18 years: contraindicated (Russian label Ranquilon (RLS copy)).
  • Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption (inherited sugar-absorption disorders): avoid the tablets, which contain lactose (Russian label Ranquilon (RLS copy)).
  • Active gallbladder disease or gallstones: inferred from the gallbladder-emptying block of CCK1 receptor antagonism seen with loxiglumide; no GB-115 data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Approved product instead of powder: Sourcing Ranquilon tablets rather than grey-market powder mitigates dosing errors and the theoretical anxiety-provoking mirror-image contaminant.
  • Label dose with meals: Taking 2 mg three times daily with or after food, maximum 6 mg daily (Russian label Ranquilon (RLS copy)), mitigates variable absorption and avoids exposure above the tested range.
  • Course length within the studied range: Keeping to the studied 28-day course mitigates unknown long-term effects, since no human safety data exist beyond four weeks.
  • No driving during early use: Not driving until the personal response is known mitigates impaired alertness from dizziness or sleepiness; the Vidal drug-reference monograph advises against driving during treatment (Vidal monograph Ranquilon).
  • Urine protein checks: A urine dipstick at baseline and after four weeks detects proteinuria, a listed adverse reaction; new persistent proteinuria is a reason to stop and obtain medical review.
  • Digestive symptom tracking: Noting new pain under the right ribs after fatty meals, or rising appetite and weight, flags possible gallbladder or appetite effects of CCK1 blockade; such pain is a reason to stop and obtain medical assessment.
  • Pregnancy testing and contraception: Testing before starting and using contraception during use mitigates fetal exposure, as pregnancy is contraindicated.

Therapeutic Protocol

Timing, cycling and titration steps without a citation reflect common practice.

  • Standard regimen: 2 mg (two 1 mg tablets) three times daily, total 6 mg/day, for 28 days, as in the label (Russian label Ranquilon (RLS copy)) and the Phase III trial (Karavayeva 2024).
  • Dose selection: In dose-finding, 6 mg/day beat placebo while 3 and 9 mg/day did not reach significance (Goncharov 2023). Higher doses offer no documented gain.
  • Alternative protocol: The Zakusov Institute, which developed and popularized the drug, used 6 mg/day for 21 days in generalized anxiety disorder (Neznamov 2019). No Western practitioner has published a protocol; online self-experimenters use unverified doses.
  • Time of day: Doses are taken at roughly the same times, 4–6 hours apart, with or after meals (Russian label Ranquilon (RLS copy)); a morning, midday and early-evening schedule fits this.
  • Half-life and splitting: Plasma half-life of 1.3–1.8 hours (Russian label Ranquilon (RLS copy)) explains the split three-times-daily schedule; a single daily dose has not been tested.
  • Genetic factors: No genetic test informs dosing; no pharmacogenetic data exist.
  • Sex: No sex-based dose adjustment exists; trials dosed men and women identically.
  • Age: Adults 18–70 were studied; no adjustment exists for older adults, in whom use is unstudied.
  • Baseline biomarkers: The Phase III trial enrolled baseline HARS scores of 18–24 with MFI-20 scores above 50 (NCT05586789). Response outside that range is unknown.
  • Pre-existing conditions: No dose adjustment is defined for kidney or liver impairment, which are unstudied (Russian label Ranquilon (RLS copy)).

Discontinuation & Cycling

  • Short-term use: GB-115 is approved as a 28-day course, not lifelong therapy (Russian label Ranquilon (RLS copy)); repeat courses have not been studied.
  • Withdrawal effects: In rats given GB-115 for 30 days, stopping caused no withdrawal anxiety, aggression or seizure susceptibility, unlike diazepam (Kolik 2011). No human withdrawal study exists.
  • Tapering: No tapering protocol is defined; trials stopped the drug abruptly after 28 days.
  • Cycling: No evidence supports cycling; tolerance did not develop over 30 days in rats (Kolik 2011), and the effect of repeated courses in humans is unknown.

Sourcing and Quality

  • Approved product: Ranquilon comes as 1 mg and 2 mg tablets (Russian label Ranquilon (RLS copy)), prescription-only in Russia (Vidal monograph Ranquilon). The 2 mg tablet was bioequivalent (delivered the same blood levels) to two 1 mg tablets (Vasilyuk 2025).
  • Grey-market powder: Outside Russia, GB-115 is sold online as an unregulated “research chemical” without manufacturing oversight; purity, dose accuracy and sterility are unverified.
  • What to look for: Third-party testing by chromatography (a purity test) plus chiral analysis (testing which mirror-image form is present) confirming the L-tryptophan form matters, because D-isomers have opposite, anxiety-provoking effects in animals (Gudasheva 2007).
  • Particle form: Micronized (finely milled) substance had higher bioavailability and longer anti-anxiety effects than crystalline substance in rats (Kolik 2015), so powder form changes effective dose.
  • Brands: Valenta Pharm is the only licensed manufacturer; no compounding pharmacy supply is known.

Practical Considerations

  • Time to effect: In a post-hoc analysis of the pilot, median HARS fell from 22 to 13 by day 7 (Dorofeeva 2022); in the dose-finding trial, anxiety separated from placebo by two weeks (Goncharov 2023).
  • Common pitfalls: Expecting an immediate benzodiazepine-like calm, dosing once daily despite the short half-life, taking it fasting, using unverified powder, or assuming longevity benefits that have never been studied.
  • Regulatory status: Registered in Russia in December 2023 as a prescription anxiolytic, per the Vidal drug reference (Vidal monograph Ranquilon). This review’s searches found no marketing authorization outside Russia; elsewhere it is used off-label from grey-market sources.
  • Cost and access: Inexpensive in Russian pharmacies (about 600–1,400 rubles per 60 tablets) (RLS pharmacy prices Ranquilon), but difficult to obtain legally elsewhere; it costs no more than generic alternatives, so payer cost incentives are not a relevant bias.

Interaction with Foundational Habits

  • Sleep: Direct, with mixed effects. The developer’s pilot reported improved anxiety-related sleep (Neznamov 2019), yet the label lists both insomnia and daytime sleepiness (Russian label Ranquilon (RLS copy)). Taking the last dose by early evening limits stimulating effects; tracking sleep quality in the first week shows the direction.
  • Nutrition: Direct. Food increases absorption, so doses go with meals. CCK is a satiety hormone, and CCK1 blockade by loxiglumide increased hunger (Beglinger 2001); tracking appetite and preferring lower-fat meals limits gallbladder strain (inferred).
  • Exercise: None documented. The label states GB-115 has no muscle-relaxant effect (Russian label Ranquilon (RLS copy)), so no impairment of training is expected; dizziness may warrant caution with balance-demanding or heavy lifts early in a course.
  • Stress management: Potentiating, indirect. GB-115 targets stress-driven anxiety, and in rhesus monkeys it lowered the cortisol to DHEA-S ratio (Panchenko 2025); it fits alongside, not instead of, psychotherapy and stress-reduction practices.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment documents anxiety severity with the Hamilton Anxiety Rating Scale or a validated self-report such as the GAD-7 (Generalized Anxiety Disorder 7-item scale), fatigue with the MFI-20, and safety markers: urine protein, liver enzymes, kidney function, and a pregnancy test for women of childbearing potential. These identify people outside the tested population, such as those with impaired kidney or liver function, and create a personal reference for judging response.

Ongoing monitoring follows the four-week course: anxiety and fatigue scores at 2 weeks and at 4 weeks (day 29), matching trial assessment points, and repeat urine protein and liver and kidney tests at 4 weeks. If a second course is considered, the same panel is repeated before restarting and at the end of each course.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
HARS total score ≥50% fall from baseline by day 29 (Phase III responder definition, Karavayeva 2024) Expected to change; defines response Trial endpoint (Karavayeva 2024). A rating scale has no laboratory reference range; scores 0–7 indicate no anxiety per the trial record (NCT05586789). Clinician-rated
MFI-20 total score ≤30 points (trial secondary endpoint, NCT05586789) Expected to change; tracks fatigue Endpoint from the trial record (NCT05586789); no laboratory reference range applies to this self-rated questionnaire
Urine protein (dipstick) Negative (standard reference range) Safety check; new proteinuria stops use Proteinuria is a listed adverse reaction (Russian label Ranquilon (RLS copy)); first-morning sample; repeat if trace
ALT and AST (liver enzymes) Within laboratory upper limit, typically ≤40 U/L (standard reference range) Safety check; abnormal values place use outside tested conditions ALT (alanine aminotransferase) and AST (aspartate aminotransferase); fasting not required. Liver impairment unstudied (Russian label Ranquilon (RLS copy)); the Phase III trial excluded values >3× upper limit (NCT05586789)
eGFR (kidney filtration) ≥60 mL/min/1.73 m² (standard reference range) Safety check; reduced values place use outside tested conditions The Phase III trial excluded eGFR ≤59 (NCT05586789); pair with serum creatinine
Pregnancy test (women of childbearing potential) Negative (standard reference range) Safety check; positive result stops use Contraindicated in pregnancy (Russian label Ranquilon (RLS copy))

Qualitative markers:

  • Day-to-day worry, tension and irritability
  • Energy and daytime fatigue
  • Sleep onset and quality, and daytime sleepiness
  • Mental clarity and attention at work
  • Appetite, weight and any pain under the right ribs after fatty meals
  • Dizziness or blurred vision

Emerging Research

  • Ongoing Phase IV comparison with fabomotizole: Randomized, open-label trial of 6 mg/day versus fabomotizole 30 mg/day in 250 adults (planned) with stress-related anxiety; primary endpoint ≥50% HARS fall at day 29; recruiting, completion estimated December 2027 (NCT06843044). A positive result would strengthen comparative evidence; a null result would weaken superiority claims.
  • Published Phase IV results: A 200-patient open-label randomized comparison reported more responders on GB-115 than fabomotizole, 63.3% versus 49.0% (Karavayeva 2026); the registry record above has not been updated to show results.
  • Completed Phase III trial: The placebo-controlled trial completed in January 2023 with no results posted to the registry (NCT05586789); results appeared in a Russian journal (Karavayeva 2024).
  • Class evidence that could weaken the case: A narrative review notes that CCK2 receptor blockers have not reliably relieved human anxiety (Ballaz 2021). Independent, non-Russian replication would test whether GB-115 escapes this pattern.
  • Open questions: Mouse data implicate CCK2 receptors (Kolik 2012) while the label names CCK1, so the effective target is unresolved. Generalized anxiety disorder has been tested only in a 31-patient pilot (Neznamov 2019); long-term safety, older adults and aging biology are unstudied.

Conclusion

GB-115 is a small protein-fragment drug taken by mouth, designed by a Russian research institute to block a brain messenger linked to fear and panic. It is a prescription anti-anxiety drug in Russia and circulates elsewhere as an unregulated powder.

For people seeking calmer stress responses, the main benefit is reduced anxiety, backed by controlled trials in adults with anxiety tied to stress-related exhaustion or difficulty adjusting to life changes. Reduced fatigue accompanies it. Gains in attention and sleep rest only on small studies without a comparison group, and reported effects on alcohol intake, mood, inflammation and stress hormones come from animals. Nothing is known about effects on aging or lifespan, so any longevity role is untested.

The risks seen so far are mild, such as headache, dizziness, sleep changes and digestive upset, with no serious events. Effects on appetite and gallbladder emptying are possible based on related drugs but have not been measured. Safety beyond a four-week course, in older adults, and with other calming drugs or supplements is unknown.

The evidence base is narrow. Nearly all human data come from the developing institute and the manufacturer, a clear conflict of interest, and no independent group outside Russia has repeated the findings. Similar drugs from Western companies failed in anxiety decades ago, for reasons still debated. GB-115 is therefore a promising but thinly tested option for short-term stress-related anxiety, with no established role in long-term health.

Top - Benefits - Risks - Protocol